Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 10/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114839 | 1.00 | GRIN1 (0.44) | GRIN1GRIN2BSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL17643108 | 1.00 | GRIN1 (0.44) | GRIN1GRIN2BSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL17643355 | 1.00 | GRIN1 (0.44) | GRIN1GRIN2BSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1740596 | 0.84 | SLC6A2 (0.53) | SLC6A4SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL797398 | 0.82 | SLC6A2 (0.52) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2114187 | 0.81 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2114185 | 0.81 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL903939 | 0.81 | SLC6A4 (0.40) | SLC6A4SLC6A2SLC6A3EPHX2 | |
| SCHEMBL24136460 | 0.81 | SLC6A4 (0.56) | GRIN1GRIN2BSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL14704876 | 0.81 | SLC6A4 (0.56) | GRIN1GRIN2BSLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145909-B2 | N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2B | NOVARTIS AG (CH) | 2024-11-19 | — | — | US | disclosed |
| EP-4282412-A2 | N-ALKYLARYL-5-OXYHETEROARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | Novartis AG (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-20220274925-A1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | CADENT THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | US | disclosed |
| EP-3974420-A1 | N-ALKYLARYL-5-OXYHETEROARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | Cadent Therapeutics, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3683207-B1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | CADENT THERAPEUTICS INC (US) | 2021-12-29 | — | — | EP | disclosed |
| US-20200369610-A1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | CADENT THERAPEUTICS, INC. (US) | 2020-11-26 | — | — | US | disclosed |
| US-10781174-B2 | N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2B | CADENT THERAPEUTICS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| EP-3683207-A1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | Cadent Therapeutics, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| EP-3197868-B1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | CADENT THERAPEUTICS INC (US) | 2020-04-15 | — | — | EP | disclosed |
| CN-106795111-B | N-alkylaryl-5-oxyaryl-octahydro-cyclopenta [ C ] pyrroles as negative allosteric modulators of NR2B | 科登特治疗公司 | 2020-04-07 | — | — | CN | disclosed |
| US-20190152912-A1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | CADENT THERAPEUTICS, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-10239835-B2 | N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of NR2B | CADENT THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180111902-A1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | LUC THERAPEUTICS, INC. (US) | 2018-04-26 | — | — | US | disclosed |
| EP-3197868-A1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | Luc Therapeutics, Inc. (US) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016049165-A1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | MNEMOSYNE PHARMACEUTICALS, INC. (US) | 2016-03-31 | — | — | WO | disclosed |
| US-8697883-B2 | Cyclopenta[C]pyrrole-2-carboxylate derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-04-15 | — | — | US | disclosed |
| US-20120095040-A1 | CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274925-A1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | GRIN2A, GRIN2C, GRIN3A | GRIN1 5/4885GRIN2B 4/4885SLC6A4 1092/4885 |
| US-12145909-B2 | N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2B | GRIN2A, GRIN2C, GRIN3A | GRIN1 5/4885GRIN2B 4/4885SLC6A4 1092/4885 |
| US-10781174-B2 | N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2B | GRIN2A, GRIN2C, GRIN3A | GRIN1 5/4885GRIN2B 4/4885SLC6A4 1092/4885 |
| US-20120095040-A1 | CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | EPOR, ACAD9, CBR1 | GRIN1 612/4885GRIN2B 609/4885SLC6A4 3490/4885 |
| US-20200369610-A1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | GRIN2A, GRIN2C, GRIN3A | GRIN1 5/4885GRIN2B 4/4885SLC6A4 1092/4885 |
| US-20180111902-A1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | OXER1, OPRL1, OXGR1 | GRIN1 31/4885GRIN2B 25/4885SLC6A4 439/4885 |
| US-10239835-B2 | N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of NR2B | OXER1, OPRL1, OXGR1 | GRIN1 31/4885GRIN2B 25/4885SLC6A4 439/4885 |
| US-20190152912-A1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | GRIN2A, GRIN2C, GRIN3A | GRIN1 5/4885GRIN2B 4/4885SLC6A4 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.